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S244 Poster Session ISAA (Kobayashi et al, BJH, 2006). Previously, outcomes for alterna-
tive donor sources have been inferior secondary to higher rates of
graft rejection, GVHD and increased mortality (Bacigalupo et al,
Blood, 2000).
Objective:Given the poor outcome of medical therapy for SAA (Be-
kassy et al, PBC, 2005) and the improvements in HLAmatching and
outcomes of transplants from alternative donor sources (Maury et al,
Haematologica, 2007), we investigated a risk-adapted AlloSCT ap-
proach in 22 consecutive patients.
Methods: Patients with\10 transfusions received reduced toxicity
conditioning: Cy 60 mg/kg + Flu 180 mg/m2 + rATG 8 mg/kg
(n5 10) or Bu 16 mg/kg + Flu 180 mg/m2 + Alemtuzumab 54 mg/
m2 (n5 3). 9 patients received myeloablative conditioning: Cy
200 mg/m2 + Flu 180 mg/m2 + rATG 8 mg/kg (n5 8) or Bu
16 mg/kg +Mel 135 mg/m2 + rATG 8 mg/kg (n5 1).
Results:M/F: 14/8, median age: 9.5 years (3-18yrs), median fol-
low-up: 19 months (1-85mos). Stem cell source: Well-MSD BM
(9 6/6, 3 5/6); PB (CD34 Selected) MUD (1 10/10, 2 9/10);
UCB (4 5/6, 3 4/6). All patients received Tacrolimus and myco-
phenolate mofetil as AGVHD prophylaxis (Osunkwo/Cairo et al,
BBMT, 2004). Median time to neutrophil and platelet engraft-
ment was 14 days (8-32 days) and 32.5 days (11-66 days), respec-
tively. 21 patients engrafted (95% CI: 77.2-99.9); 1 patient had
primary graft failure (4.5%). Day +100 mean chimerism was
96.4%, and patients did not differ by intensity of conditioning.
Among the 7 patients (31.8%) who developed grade 2-4
GVHD, risk was not associated with conditioning regimen, do-
nor source or HLA match. One-year OS was 71.6% (standard
error 9.8%, 95% CI 50.7-92.6%) and an association was not de-
tectable in regards to donor source, HLA disparity or condition-
ing intensity. Six patients died (27.3%) (multiorgan failure: 3,
extensive GVHD: 1, fungal infection: 1, TMA: 1). 3 patients
had secondary graft failure (16.6%) and 2 patients required a sec-
ond transplant secondary to adenovirus and pure red blood cell
aplasia. Our data suggest that a risk-adapted approach to Al-
loSCT from related and alternative donor sources is a feasible
strategy for treatment of newly diagnosed pediatric patients
with SAA.231
25-HYDROXY VITAMIN D DEFICIENCY IN PEDIATRIC PATIENTS FOL-
LOWING HEMATOPOIETIC STEM CELL TRANSPLANT
Apfelbaum, E.1, Vrooman, L.M.1, Lehmann, L.E.1, Bechard, L.J.2,
Duncan, C.N.1 1Dana-Farber Cancer Institute, Boston, MA; 2Children’s
Hospital, Boston, MA
Pediatric patients following hematopoietic stem cell transplant
(HSCT) are at increased risk for vitamin D deficiency due to
lack of sun exposure and sunscreen use, some medications, and
dietary insufficiency. We investigated the incidence of 25-OH vi-
tamin D deficiency in pediatric patients following HSCT. The
study population included 90 patients (52 male, 38 female). 11
subjects had autologous HSCTs and 79 received allogeneic
HSCTs. The median time from transplant was 177 days (range
13-6873 days). 76% of subjects were Caucasian, 8% Hispanic,
7% Asian, 5% African American, and 4% mixed ethnicity. The
underlying diseases were ALL (27.8%), AML/MDS (20%), non-
malignant hematologic disorder (18.9%), solid tumor (12.3%),
immunodeficiency (7.8%), CML (4.4%), lymphoma (4.4%), and
other disorder (4.4%). 27.8% of patients received corticosteroids
and 51.1% took calcineurin inhibitors at the time of enrollment.
At enrollment, 5 patients received multivitamins and 4 patients
took vitamin D supplements. The incidence of 25-OH vitamin
D insufficiency, defined as a level less than 30 ng/mL, was
87%. 53% of patients were deficient with levels less than 20
ng/mL. The median 25-OH vitamin D level was 18 ng/mL
(mean 21.1 ng/mL). Patients with deficiency were prescribed
50,000 IU of ergocalciferol orally once weekly for 6 weeks. 47 pa-
tients received supplementation and post-supplementation values
were available for 40 patients. 5 patients died prior to repeat test-
ing and levels were missing for 2 patients. Repeat post-supple-
mentation testing revealed a median level of 30 ng/mL. 12.5%(n5 5) of those supplemented remained deficient 20 ng/mL and
47.5% (n5 19) remained insufficient. This study highlights the
need to monitor pediatric patients for vitamin D deficiency. A
better understanding of the risk factors and appropriate treatment
for vitamin D deficiency following HSCT is needed.232
BUSULFAN + FLUDARABINE, AN EFFECTIVE AND LOW TOXIC REGIMEN
IN CHILDREN WITH MALIGNANT AND NON-MALIGNANT DISEASES
Flinsenberg, T.W.H.1, Bartelink, I.H.2, Ververs, T.F.T.T.2,
Bierings, M.1, Boelens, J.J.1 1UMCU, Utrecht, Netherlands; 2UMCU,
Utrecht, Netherlands
Background: Busulfan as myeloablative agent is used in condition-
ing prior to pediatricHSCT:mainly in combination with cyclophos-
phomide. We recently found a clear association between busulfan
exposure and outcomes (survival/event free survival). However, tox-
icity leading tomorbidity and associatedmortality remains a limiting
factor. Comparison studies in adults showed a favorable toxicity pro-
file for fludarabine + busulfan (FludBu) compared to the conven-
tional BuCy regimen. In paediatrics, limited data is available
regarding this regimen. FludBu was recently introduced to replace
the BuCy regimen in our center for myeloid malignancies and all
non-malignant indications. We compared the outcomes with our
BuCy historic controls.
Methods: Fludarabine was given in 1 hour prior to a 3 hour infusion
of once daily busulfan. The target area under the curve (AUC) for Bu
was. 74 mg*h/L (in total) in both groups. Busulfan dose targeting,
based on therapeutic drug monitoring was performed before the sec-
ond dose. Primary endpoints were event free survival (EFS) and sur-
vival. Secondary endpoints were acute graft-versus-host disease
(aGvHD), neutropenic period and the number of erythrocytes and
thrombocytes transfusions. A risk factor analysis was performed us-
ing univariable and multivariable COX regression.
Results: 13 patients were included in the FludBu group (median
follow up median 119 days; range 42-1593) and 44 in the BuCy
group (710 days; range 6-1686). The groups were comparable re-
garding donor source, age, gender, indication for SCT and match-
grade. EFS and Survival in FludBu and BuCy was 85% vs 71%
(NS) and 92% vs. 73% (NS), respectively. No difference in
aGvHD ($grade 2) was found between the 2 groups. The period
of neutropenia was median 12 in the FludBu group compared to
20.5 in the BuCy group (HR 0.38, p5 0.05, CI95% 0.20-0.75).
The median number of erythrocytes transfusion was 1 (range 1-
13) in the FludBu group and 5 (0-22) in the BuCy group
(p5 0.20) and thrombocyte infusions 5 (range 0-33) vs 10 (range
2-44)(p5 0,15).
Conclusions: Busulfan with a total target AUC of .74 mg*h/l in
combination fludarabine showed to be an effective and low toxic reg-
imen. Interesting is the significantly shorter neutropenic period and
lower number of transfusions (erythrocytes and thrombocytes)
needed in the FludBu group in comparison to BuCy. Although
a small series, FludBu showed promising results. Further follow up
and extension of the series is needed.233
PERI-TRANSPLANT INFECTIONS IN UNRELATED CORD BLOOD TRANS-
PLANTATION AND THEIR INFLUENCE ON OUTCOME
Alsultan, A., Giller, R.H., Gao, D., Bathurst, J., Hild, E.,
Foreman, N.K., Keating, A., Quinones, R.R. The Children’s Hospital
and University of Colorado Denver, Aurora, CO
Infection in the peri-transplant period is a major cause of
morbidity and mortality post-transplant. The nature of peri-
transplant infections and their influence on outcome post unre-
lated cord blood transplant (UCBT) need to be further eluci-
dated.
Methods:We reviewed peri-transplant infections in 81 consecutive
UCBT. All culture-documented infections were reviewed starting 3
months pre-transplant through the first 100 days post-transplant.
Acute GVHD (aGVHD) II-IV, aGVHD III-IV, chronic GVHD
(cGVHD), and event free survival (EFS) were used as endpoints.
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gender, diagnosis, disease status, degree of HLA-match, blood type
match, recipient CMV serology, use of TBI, infused NC, infused
CD34, CMV reactivation, and presence of aGVHD or cGVHD.
Results: The table shows the incidence and timing of infections in
the peri-transplant period. Sites of infection were reported from
day -90 to -1 and from day 0 to +100, respectively. Bacterial infec-
tions were bacteremia (52%,66%); ENT/pulmonary (21%,7%);
UTI (17%,6%); C. difficile (6%,19.5%); and other (4%,1.5%). Viral
infections were respiratory (56%,29%) and non-respiratory
(44%,71%). Fungal infections were fungemia (50%,73%) and si-
nus/pulmonary infection (50%,27%). On univariate (UV) analysis,
factors associated with a significant risk of aGVHD II-IV included:
infused CD34 cell dose.1 X105/kg (P5 0.04), non-malignant dis-
orders (P5 0.04), and presence of bacterial infection within 3
months pre-transplant (P5 0.04). High-infused CD34 remained
significant on MV analysis. None of the variables were significant
for aGVHD III-IV. Presence of aGVHD (P5 0.002) was the only
significant risk factor for cGVHD. Infused CD34# 1 X105/kg
(P5 0.01) and presence of fungal infection within 100 days post-
transplant (P\0.001) were significantly associated with poor EFS
at 1 year post-transplant.
Conclusion: Bacterial infection pre-transplant was a significant risk
factor for grade II-IV aGVHD on UV analysis. This may be related
to effective anti-bacterial therapy allowing shorter delays in proceed-
ing to transplant compared to either viral or fungal infections. This
could result in an increased systemic inflammatory milieu persisting
into the transplant period and adding to the cytokine storm. The
presence of fungal infection post-transplant was strongly associated
with increasedmortality. Of note, peri-transplant viral infections had
no influence on any of the outcomes.
Incidence and types of infection in the peri-transplant period.
Infections from Day -90 to -1 Infections from Day 0 to 1100No.
(% total)Median
pre-transplant
day of last
infection (range)
No.
(% total)Median
post-transplant
day of first
infection (range)Bacterial 32 (41%) 221 (21 to -83) 49 (62%) 128 (0 to 190)
Fungal 4 (5%) 269 (219 to -90) 11 (14%) 118 (13 to 177)
Viral 34 (43%) 240 (21 to -89) 21 (27%) 124 (0 to 191)
Any 51 (65%) 231 (21 to -90) 70 (89%) 124 (0 to 191)Each type of infection (e.g. bacterial) was listed only once per patient,
even if they had several infections of that type.234
DIAGNOSTIC UTILITY AND COMPLICATIONS OF LIVER BIOPSY IN THE
PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT POPULATION
Oshrine, B.R.1, Lehmann, L.2, Duncan, C.N.2 1Children’s Hospital, Bos-
ton, MA; 2Dana-Farber Cancer Institute, Boston, MA
Liver dysfunction (LD) is common following pediatric hema-
topoietic stem cell transplantation (HSCT). Often the etiology
of LD can be determined based on historical, physical exam,
laboratory, or imaging findings, but a liver biopsy may be nec-
essary to diagnosis the cause of LD and institute appropriate
therapy. We report our institution’s experience with liver biop-
sies in 356 consecutive HSCT patients from January 1, 2004
to December 31, 2008, to determine the clinical utility and
overall safety of this diagnostic modality. During the study pe-
riod, 16 (4.5%) patients underwent 18 liver biopsies, all of which
occurred following allogeneic HSCT. The median age at the
time of HSCT was 141.5 months, and the median time from
HSCT to liver biopsy was 205.5 days. All patients had transam-
inase elevation (median AST 208.5 units/L; ALT 331 units/L),
and 67% had hyperbilirubinemia (median total bilirubin
8.1 mg/dL; direct bilirubin 5.75 mg/dL). Imaging prior to biopsy
was performed in 17/18 cases. The most commonly utilized
method of biopsy was the imaging-guided percutaneous ap-proach, performed in 12/18 cases. Five biopsies were done trans-
jugularly and one was performed during open laparotomy. In all
cases a histopathologic diagnosis was made. The most common
diagnosis was graft-versus-host disease (GVHD), present in 15
of the 18 specimens, followed by iron overload (IO) (9/18).
Other histologic diagnoses included viral, toxic/metabolic injury,
early sinusoidal obstructive syndrome, and drug-induced damage.
In 12 cases, management was modified based on biopsy results.
Immunosuppression was added or adjusted to treat GVHD in 10
cases. In two cases phlebotomy or chelation therapy was recom-
mended for IO, despite this diagnosis being present in nine
specimens. Complications occurred after five biopsies (28%),
four of which were performed transjugularly. No complications
were observed after percutaneous biopsies. The most common
complication was intra-/extra-hepatic hemorrhage and need for
red blood cell transfusion (3/5). Two patients required transfer
to the intensive care unit for biopsy-related complications. In
two cases a second procedure was required to manage a bi-
opsy-related complication (both requiring hepatic artery emboli-
zation after transjugular biopsy). We conclude that while liver
biopsy successfully yields a diagnosis of the etiology of LD, it
is accompanied by high rates of complications, particularly
with the transjugular approach.235
A PILOT STUDY OF REDUCED INTENSITY CONDITIONING (RIC)WITH BU-
SULFAN, FLUDARABINE AND ALEMTUZUMAB (BFA) PRIOR TO ALLOGE-
NEIC STEM CELL TRANSPLANTATION (ALLOSCT) IN CHILDREN AND
ADOLESCENT (C&A) RECIPIENTS
Styczynski, J.1,2, Tallamy, B.1, van de Ven, C.1, Harrison, L.1,
Morris, E.1, Satwani, P.1, Bhatia, M.1, George, D.1, Bradley, M.B.1,
Garvin, J.H.1, Schwartz, J.3, Baxter-Lowe, L.A.4, Cairo, M.S.1,3,5
1Morgan Stanley Childrens Hospital, New York-Presbyterian, Columbia
University, NY; 2Collegium Medicum UMK, Bydgoszcz, Poland; 3Co-
lumbia University, New York, NY; 4University of California, San Fran-
cisco, CA; 5Columbia University, New York, NY
Background: AlloSCT following conditioning with fludarabine,
busulfan, and alemtuzumab (BFA) in adult pts with AML/MDS
was safe and permitted durable donor engraftment (Ho et al, Blood,
2004). There is a paucity of data of RIC with fludarabine, busulfan
and rATG and none with alemtuzumab (BFA) in pediatric AlloSCT
recipients.
Objective: To determine the safety and percentage of mixed donor
chimerism following a BFA RIC AlloSCT in C&A.
Methods:We report results of a pilot study of BFA RICAlloSCT in
12 recipients (\21 yrs) withmalignant (n5 7; 5 average-risk, 2 poor-
risk: CML 4, APML 1, NHL 1, HTLV-LL 1), and non-malignant
diseases (n5 5: SAA 3, Scleroderma 1,Wolman’sDisease 1).Median
age 16 (2-20) yrs, 6F:6 M. Stem cell source: 2 unrelated cord blood
(UCB) (2 5/6), 1 unrelated BM (10/10), 2 related (1 6/6, 1 5/6) and
7 unrelated PBSC (3 8/10, 3 9/10, 1 10/10). Positive CD34 selection
was done in 5 unrelated PBSCT. RIC: fludarabine (180 mg/m2, 6
days), busulfan (16 mg/kg #4 yrs and 12.8 mg/kg for .4 yrs, 4
days, total 8 doses) + alemtuzumab (54 mg/m2, 5 escalating doses).
GVHD prophylaxis: FK506/MMF. STR loci were used to measure
donor chimerism.
Results:Median time to myeloid engraftment was 16d (16d vs. 16d
for unselected PBSC/BM/CB vs. selected PBSC recipients, ns); me-
dian time to platelet engraftment: 31d (27d vs. 35d for unselected
PBSC/BM/CB vs. selected PBSC recipients, ns). The probability
of developing $grade II, $grade III AGVHD and CGVHD was
41.6%, 25%, and 9% respectively. There was 1 primary graft failure
(GF), and no secondaryGF.Medianmixed donor chimerism day 100
and 1 yr: 99% and 96%, respectively; $90% of recipients achieved
$80%donor chimerism.The 3 yrOSwas 91.76 8% (100% forma-
lignant vs 80% for non-malignant diseases, ns). The probability of
3 yr OS for patients receiving CD34-selected PBSC was 100% and
receiving non-CD34-selected PBSC/BM/UCB was 85.7% (ns). 11
pts remain alive at median 2.8 (0.3-6.8) yrs. Only 1/12 developed
$grade III toxicity (liver grade IV). Incidence of transplant-related
mortality was 1/12 (9%). 1 patient died of IFI at day +40. Infectious
complications included: CVL bacteremia (6/12), 2 IFI and 3 other
